Predictive Value of Annenxin A1 for Disease Severity and Prognosis in Patients with Community-Acquired Pneumonia
Diagnostics · 21.01.2023 · 13 (3) · 396
DOI: 10.3390/diagnostics13030396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 21.01.2023. Verfasst von Minghao Gu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao 266011, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qingdao Municipal Hospital Clinical Diagnosis and Treatment Technology Innovation Fund.
Abstract (Originalsprache)
This prospective, single-center study evaluated the clinical utility of annenxin (Anx)A1 level as a biomarker for determining the severity of illness and predicting the risk of death in hospitalized patients with community-acquired pneumonia (CAP). A total of 105 patients (53 with severe [S]CAP, 52 with non-SCAP) were enrolled from December 2020 to June 2021. Demographic and clinical data were recorded. Serum AnxA1 concentration on days one and six after admission was measured by enzyme-linked immunosorbent assay. AnxA1 level at admission was significantly higher in SCAP patients than in non-SCAP patients (p < 0.001) irrespective of CAP etiology and was positively correlated with Pneumonia Severity Index and Confusion, Uremia, Respiratory Rate, Blood Pressure, and Age ≥ 65 Years score. AnxA1 level was significantly lower on day six after treatment than on day one (p = 0.01). Disease severity was significantly higher in patents with AnxA1 level ≥254.13 ng/mL than in those with a level 670.84 ng/mL. These results indicate that AnxA1 is a useful biomarker for early diagnosis and prognostic assessment of CAP.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao 266011, China.
- Medical School of Qingdao University, Qingdao 266071, China.
ORCID-Profile: Minghao Gu
Förderung
- Qingdao Municipal Hospital Clinical Diagnosis and Treatment Technology Innovation Fund
Zitieren
APA
Gu, M., Han, X., Liu, X., Sui, F., Zhang, Q., & Pan, S. (2023). Predictive Value of Annenxin A1 for Disease Severity and Prognosis in Patients with Community-Acquired Pneumonia. Diagnostics, 13(3), 396. https://doi.org/10.3390/diagnostics13030396
Vancouver
Gu M, Han X, Liu X, Sui F, Zhang Q, Pan S. Predictive Value of Annenxin A1 for Disease Severity and Prognosis in Patients with Community-Acquired Pneumonia. Diagnostics. 2023;13(3):396. doi:10.3390/diagnostics13030396
BibTeX
@article{Gu2023,
author = {Gu, Minghao and Han, Xiudi and Liu, Xuedong and Sui, Fengxiang and Zhang, Quansan and Pan, Shengqi},
title = {Predictive Value of Annenxin A1 for Disease Severity and Prognosis in Patients with Community-Acquired Pneumonia},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {3},
pages = {396},
doi = {10.3390/diagnostics13030396}
}
EUVIMED